What is the purpose of registration submission guide, based on data from scientific literature?

Publication of the Public Consultation for the review of RDC 200 - what is new?

NEW REGULATORY FRAMEWORK OF API

COVID-19: What facilities is ANVISA providing at this time of crisis?

Why are 24% of drug registrations still rejected?

API, BPF and drug dossier - How to align the processes to ensure success in registration?

NEW API REGULATORY FRAMEWORK: Will ANVISA and international manufacturers be prepared?

Publication of the new API regulatory framework: what is essential to know?

Outcome of the RDC 200 Review Working Group meeting - 02/05/20

Cannabis: the rules of the new regulation system.

Everything you need to know about the new rules for Drug Renewal.

API: Why control it?

CTD - Why?

Which points generate the most rejections and demands in innovative drug processes?

DDCM- What are the most demanding requirements by ANVISA?

Practical aspects of biosimilar registration

Comparability of biosimilars: unraveling this enigma

ANVISA’S new era: is the regulatory sector prepared for this?